CSLHAM:CSJ +0.07%73 Price-to-Owner-Earnings is 11.32 as of Jun. 24, 2026, which is 74% below its 10-year median of 43.18. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €170.71 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 207 Biotechnology companies, CSL ranks better than 71.98% on this metric.
As of today (2026-06-24), CSL's share price is €68.23.
CSL's Owner Earnings per Share (TTM) ended in Jun. 2025 was €6.03. It's Price-to-Owner-Earnings for today is 11.32.
The historical rank and industry rank for CSL's Price-to-Owner-Earnings or its related term are showing as below:
HAM:CSJ'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.58 Med: 43.18 Max: 59.87
Current: 11.54
During the past 13 years, the highest Price-to-Owner-Earnings of CSL was 59.87. The lowest was 9.58. And the median was 43.18.
HAM:CSJ's Price-to-Owner-Earnings is ranked better than 71.98% of 207
companies
in the Biotechnology industry
Industry Median: 24.14
vs HAM:CSJ: 11.54
As of today (2026-06-24), CSL's share price is €68.23.
CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.70. Therefore, CSL's PE Ratio (TTM) for today is 97.47.
As of today (2026-06-24), CSL's share price is €68.23.
CSL's EPS without NRI for the trailing twelve months (TTM) ended in was €3.07. Therefore, CSL's PE Ratio without NRI for today is 22.23.
During the past 13 years, CSL's highestPE Ratio without NRI was 55.28. The lowest was 10.19. And the median was 39.22.
The historical data trend for CSL's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:CSJ vs VRTX, REGN, ALNY: Price-to-Owner-Earnings Comparison
For the Biotechnology subindustry, CSL's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Price-to-Owner-Earnings vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where CSL's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
CSL's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Owner-Earnings of 11.32 mean?
CSL (HAM:CSJ) has a Price-to-Owner-Earnings of 11.32 as of Jun. 24, 2026. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on CSL and its competitors. This is 74% below median its historical median of 43.18. Over the past decade, CSL's Price-to-Owner-Earnings has ranged from 9.58 to 59.87. According to the industry distribution chart, CSL ranks #58 out of 207 companies in the Biotechnology industry, placing it in the top 28%.
Is CSL's Price-to-Owner-Earnings too high?
CSL's current Price-to-Owner-Earnings of 11.32 is 74% below median its 10-year median of 43.18. Over the past 10 years, this metric has ranged from a low of 9.58 to a high of 59.87. The Biotechnology industry median Price-to-Owner-Earnings is 24.14. CSL's value of 11.32 is 53.1% below this industry median. Based on the distribution chart, CSL ranks #58 out of 207 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Price-to-Owner-Earnings compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #58 out of 207 companies for Price-to-Owner-Earnings. This puts CSL in the upper half of its industry. The industry median Price-to-Owner-Earnings is 24.14. CSL's value of 11.32 is 53.1% below this benchmark. Historically, CSL's own Price-to-Owner-Earnings has ranged from 9.58 to 59.87 over the past decade. While the company's 10-year median is 43.18 vs. the industry median of 24.14, CSL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Owner-Earnings for a Biotechnology company?
The median Price-to-Owner-Earnings among Biotechnology companies is 24.14, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Owner-Earnings significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Owner-Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Price-to-Owner-Earnings of 11.32 is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Owner-Earnings mean?
A high Price-to-Owner-Earnings can signal that a stock is expensive relative to its fundamentals. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on CSL and its competitors. For the Biotechnology industry, the median Price-to-Owner-Earnings is 24.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Price-to-Owner-Earnings is 11.32, which is 74% below median its own 10-year median of 43.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €170.71, compared to a current price of €68.23 — trading 60% below its estimated fair value. The current Price-to-Owner-Earnings is 11.32, which is 74% below median its 10-year median of 43.18 and 53.1% below the Biotechnology industry median of 24.14. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Owner-Earnings calculated?
Price-to-Owner-Earnings is calculated from a company's financial statements. For CSL (HAM:CSJ), the current Price-to-Owner-Earnings is 11.32 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (HAM:CSJ) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of €68.23 is trading 60% below its estimated GF Value™ of €170.71.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for HAM:CSJ:
Price-to-Owner-Earnings: 11.32 (74% below median its 10-year median of 43.18)
GF Value™: €170.71 vs. price of €68.23 (60% below fair value)
Industry Position: 53.1% below the Biotechnology median (#58 of 207)
No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for HAM:CSJ
Price-to-Owner-Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:CSJ has been successfully added to your 
